Shareholder Alert: The Ademi Firm investigates whether Metsera Inc. is obtaining a Fair Price for its Public Shareholders

Core Points - Metsera (Nasdaq: MTSR) is involved in a transaction with Pfizer, where shareholders will receive $47.50 per share, resulting in an enterprise value of approximately $4.9 billion [2][3] - The transaction agreement includes provisions that significantly limit competing offers for Metsera, imposing penalties if a competing bid is accepted [3] Investigation Details - The Ademi Firm is investigating potential breaches of fiduciary duty by Metsera's board of directors regarding their responsibilities to shareholders in light of the transaction with Pfizer [1][3] - The investigation focuses on whether the board is acting in the best interests of all shareholders, given the substantial benefits insiders will receive from change of control arrangements [2][3]